Systematic Review of Oral Therapy for the Treatment of Symptoms of Bladder Pain Syndrome: The Brazilian Guidelines

Santos, Thaís Guimarães dos; Miranda, Isabela; Nygaard, Christiana Campani; Schreiner, Lucas; Castro, Rodrigo de Aquino; Haddad, JM

doi:10.1055/s-0037-1609049

Cited by 6 publications

(5 citation statements)

References 21 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lusty et al found that the only therapies that seem to align between this reported effectiveness and published efficacy include amitriptyline (with the strongest alignment), hydroxyzine, PPS, and/or combinations [15]. Therefore, orally administered amitriptyline is still an efficacious medicine for IC/BPS and would be the first treatment offered [16].…”

Section: Discussionmentioning

confidence: 99%

Amitriptyline plus hydrodistension versus hydrodistension alone for treating interstitial cystitis bladder pain syndrome

Chen¹,

Zhang²,

Chen³

et al. 2022

Med Clin Sci

View full text Add to dashboard Cite

Purpose: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating condition that is difficult to diagnose and treat. The aim of this study was to investigate whether a combination treatment of amitriptyline after bladder hydrodistension is more beneficial for IC/BPS patient. Methods: Seventy-six patients’ dates diagnosed with IC/BPS were collected: the hydrodistension group (34 patients) and the combination group (42 patients), which received amitriptyline (25 mg ~ 50 mg/d) for 3 months following hydrodistension. The efficacy was evaluated at the 3rd and 6th months by using index scores. In addition, adverse events of amitriptyline and hydrodistension were recorded. Results: There was no difference in two groups at baseline. The ICSI, ICPI, AIS, SAS, OABSS, VAS and FVC scores improve significantly in the combination group than in the hydrodistension group at 3 months after hydrodistension . After 3 months of amitriptyline withdrawal, obvious improvement in the combination group was observed only for the AIS at the 6th month. At the 6th month, the indexes of the two groups still improved significantly compared with those recorded prehydrodistension; however, there was no difference in the improvement of maximum bladder volume in both groups before and after hydrodistension (P > 0.05). The adverse events of amitriptyline all were in the tolerable range. Conclusions: Hydrodistension under general anesthesia effectively relieved IC patients’ symptoms for at least 6 months. The three-month usage of amitriptyline alleviated the symptoms and problems more quickly and safely after hydrodistension in patients with IC/BPS.

show abstract

Section: Discussionmentioning

confidence: 99%

Amitriptyline plus hydrodistension versus hydrodistension alone for treating interstitial cystitis bladder pain syndrome

Chen¹,

Zhang²,

Chen³

et al. 2022

Med Clin Sci

View full text Add to dashboard Cite

show abstract

“…Pentosan polysulfate sodium is the only U.S. Food and Drug Administration (FDA) approved oral drug to treat IC/BPS, and is the most well-studied oral UCPPS medication . The drug has shown the most success of any oral treatment used as a monotherapy (Davis et al, 2008;Santos et al, 2018), but effects still vary significantly among patients and symptom presentation. Additional GAG-replenishing treatments have also been investigated.…”

Section: Conventional Therapies For Ucppsmentioning

confidence: 99%

Therapeutic approaches for UCPPS management: research advances, experimental targets, and future directions

Ashraf,

Clarkson,

Malykhina

2024

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Urologic Chronic Pelvic Pain Syndrome (UCPPS) is a painful chronic condition with persistent pain originating from the pelvis that often leads to detrimental lifestyle changes in the affected patients. The syndrome develops in both sexes, with an estimated prevalence of 5.7% to 26.6% worldwide. This narrative review summarizes currently recommended therapies for UCPPS, followed by the latest animal model findings and clinical research advances in the field. The diagnosis of UCPPS by clinicians has room for improvement despite the changes in the past decade aiming to decrease the time to treatment. Therapeutic approaches targeting growth factors (i.e., NGF, VEGF), amniotic bladder therapy and stem cell treatments gain more attention as experimental treatment options for UCPPS. The development of novel diagnostic tests based on the latest advances in urinary biomarkers would be beneficial to assist with the clinical diagnosis of UCPPS. Future research directions should address the role of chronic psychological stress and the mechanisms of pain refractory to conventional management strategies in UCPPS etiology. Testing the applicability of cognitive behavioral therapy in this cohort of UCPPS patients might be promising to increase their QoL. The search for novel lead compounds and innovative drug delivery systems requires clinically relevant translational animal models. The role of autoimmune responses triggered by environmental factors is another promising research direction to clarify the impact of the immune system in UCPPS pathophysiology. SIGNIFICANCE STATEMENTThis minireview provides an up-to-date summary of the therapeutic approaches for UCPPS with focus on recent advancements in the clinical diagnosis and treatments of the This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward.

show abstract

“… 160 Amitriptyline, which is widely used and inexpensive, is a second-line option, with some analgesic, anticholinergic, sedative, anxiolytic and antidepressant effects, which could improve urinary frequency if the patient is able to tolerate at least 50 mg/day. 135 …”

Section: Pharmacological Treatmentmentioning

confidence: 99%

Current Challenges in the Management of Chronic Pelvic Pain in Women: From Bench to Bedside

Siqueira-Campos¹,

Deus²,

Neto³

et al. 2022

IJWH

View full text Add to dashboard Cite

Chronic pelvic pain (CPP) affects a significant proportion of women worldwide And has a negative impact on several aspects of these women’s lives including mental health, work, relationships and sexual function, among others. This set of factors ultimately reflects negatively on quality Of life. The physiopathology of CPP is complex and remains to be fully clarified; however, recent advances have increased understanding of the mechanisms involved in chronic pain in general, and more specifically, CPP. Nonetheless, even when a detailed clinical history is obtained, meticulous physical examination is performed and imaging resources are appropriately used, the organic cause of the pain may still fail to be identified in a substantial number of women with CPP. Management of CPP may therefore be challenging. This narrative review was aimed at adding to the available literature on the subject, presenting and discussing the principal characteristics of CPP in women. The paper highlights gaps in the literature while providing the most up-to-date evidence associated with the physiopathology and classification of pain, its diagnosis and treatment. In addition, current challenges in the management of women with CPP are discussed.

show abstract

Systematic Review of Oral Therapy for the Treatment of Symptoms of Bladder Pain Syndrome: The Brazilian Guidelines

Cited by 6 publications

References 21 publications

Amitriptyline plus hydrodistension versus hydrodistension alone for treating interstitial cystitis bladder pain syndrome

Amitriptyline plus hydrodistension versus hydrodistension alone for treating interstitial cystitis bladder pain syndrome

Therapeutic approaches for UCPPS management: research advances, experimental targets, and future directions

Current Challenges in the Management of Chronic Pelvic Pain in Women: From Bench to Bedside

Contact Info

Product

Resources

About